Gilead Sciences Aktie News

Gilead Sciences Inc  (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.

Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript

The biopharmaceutical company may start to offer two cancer therapies and an additional HIV treatment option this year.

Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.

Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light guidance for 2026.

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Dividend--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 3.8% in the company's quarterly cash dividend, beginning in the first quarter of 2026. The increase will result in a quarterly dividend of $0.82 per share of common stock. The dividend is payable on March 30, 2026, to stockholde...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025. “Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch of Yeztugo, the world's first twice-yearly HIV prevention therapy, and continued growth for Bikta...

I rate Gilead Sciences (GILD) a 'Buy' with a $191 price target. It offers an attractive 2.1% dividend yield and low volatility. GILD's revenue is anchored by Biktarvy, protected by exclusivity through 2036, reducing near-term patent cliff risk versus peers. Strong profitability, efficient capital allocation, and robust dividend growth capacity underpin GILD's investment case for safety and income.